Jordan M Cloyd1, Graciela M Nogueras-González2, Laura R Prakash1, Maria Q B Petzel1, Nathan H Parker1, An T Ngo-Huang3, David Fogelman4, Jason W Denbo1, Naveen Garg5, Michael P Kim1, Jeffrey E Lee1, Ching-Wei D Tzeng1, Jason B Fleming1, Matthew H G Katz6. 1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484, PO Box 301402, Houston, TX, 77230-1402, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1484, PO Box 301402, Houston, TX, 77230-1402, USA. mhgkatz@mdanderson.org.
Abstract
BACKGROUND: The changes in body composition that occur in response to therapy for localized pancreatic ductal adenocarcinoma (PDAC) and during the early survivorship period, as well as their clinical significance, are poorly understood. METHODS: One hundred twenty-seven consecutive patients with PDAC who received preoperative therapy followed by pancreatoduodenectomy (PD) at a single institution between 2009 and 2012 were longitudinally evaluated. Changes in skeletal muscle (SKM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were measured on serial computed tomography images obtained upon presentation, prior to pancreatectomy, and approximately 3 and 12 months after surgery. RESULTS: Prior to therapy, patients' mean baseline BMI was 26.5 ± 4.7 kg/m2 and 63.0% met radiographic criteria for sarcopenia. During a mean 5.4 ± 2.3 months of preoperative therapy, minimal changes in SKM (- 0.5 ± 7.8%, p > 0.05), VAT (- 1.8 ± 62.6%, p < 0.001), and SAT (- 4.8 ± 27.7%, p < 0.001) were observed. In contrast, clinically significant changes were observed on postoperative CT compared to baseline anthropometry: SKM - 4.1 ± 10.7%, VAT - 38.7 ± 30.2%, and SAT - 24.1 ± 22.6% (all p < 0.001) and these changes persisted at one year following PD. While anthropometric changes during preoperative therapy were not independently associated with survival, SKM gain between the postoperative period and one-year follow-up was associated with improved overall survival (OR 0.50, 95% CI 0.29-0.87). CONCLUSIONS: In contrast to the minor changes that occur during preoperative therapy for PDAC, significant losses in key anthropometric parameters tend to occur over the first year following PD. Ongoing SKM loss in the postoperative period may represent an early marker for worse outcomes.
BACKGROUND: The changes in body composition that occur in response to therapy for localized pancreatic ductal adenocarcinoma (PDAC) and during the early survivorship period, as well as their clinical significance, are poorly understood. METHODS: One hundred twenty-seven consecutive patients with PDAC who received preoperative therapy followed by pancreatoduodenectomy (PD) at a single institution between 2009 and 2012 were longitudinally evaluated. Changes in skeletal muscle (SKM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were measured on serial computed tomography images obtained upon presentation, prior to pancreatectomy, and approximately 3 and 12 months after surgery. RESULTS: Prior to therapy, patients' mean baseline BMI was 26.5 ± 4.7 kg/m2 and 63.0% met radiographic criteria for sarcopenia. During a mean 5.4 ± 2.3 months of preoperative therapy, minimal changes in SKM (- 0.5 ± 7.8%, p > 0.05), VAT (- 1.8 ± 62.6%, p < 0.001), and SAT (- 4.8 ± 27.7%, p < 0.001) were observed. In contrast, clinically significant changes were observed on postoperative CT compared to baseline anthropometry: SKM - 4.1 ± 10.7%, VAT - 38.7 ± 30.2%, and SAT - 24.1 ± 22.6% (all p < 0.001) and these changes persisted at one year following PD. While anthropometric changes during preoperative therapy were not independently associated with survival, SKM gain between the postoperative period and one-year follow-up was associated with improved overall survival (OR 0.50, 95% CI 0.29-0.87). CONCLUSIONS: In contrast to the minor changes that occur during preoperative therapy for PDAC, significant losses in key anthropometric parameters tend to occur over the first year following PD. Ongoing SKM loss in the postoperative period may represent an early marker for worse outcomes.
Authors: Andrew J Benjamin; Mary M Buschmann; Andrew Schneider; Brian A Derstine; Jeffrey F Friedman; Stewart C Wang; William Dale; Kevin K Roggin Journal: J Gastrointest Surg Date: 2017-03-24 Impact factor: 3.452
Authors: Neda Amini; Gaya Spolverato; Rohan Gupta; Georgios A Margonis; Yuhree Kim; Doris Wagner; Neda Rezaee; Matthew J Weiss; Christopher L Wolfgang; Martin M Makary; Ihab R Kamel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2015-04-30 Impact factor: 3.452
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Jeremy L Davis; Luke V Selby; Joanne F Chou; Mark Schattner; David H Ilson; Marinela Capanu; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: Ann Surg Oncol Date: 2016-01-05 Impact factor: 5.344
Authors: M Muscaritoli; S D Anker; J Argilés; Z Aversa; J M Bauer; G Biolo; Y Boirie; I Bosaeus; T Cederholm; P Costelli; K C Fearon; A Laviano; M Maggio; F Rossi Fanelli; S M Schneider; A Schols; C C Sieber Journal: Clin Nutr Date: 2010-01-08 Impact factor: 7.324
Authors: Connie Yip; Vicky Goh; Andrew Davies; James Gossage; Rosalind Mitchell-Hay; Orla Hynes; Nick Maisey; Paul Ross; Andrew Gaya; David B Landau; Gary J Cook; Nyree Griffin; Robert Mason Journal: Eur Radiol Date: 2014-02-18 Impact factor: 5.315
Authors: David R Fogelman; Holly Holmes; Khalil Mohammed; Matthew H G Katz; Carla M Prado; Jessica Lieffers; Naveen Garg; Gauri R Varadhachary; Rachna Shroff; Michael J Overman; Christopher Garrett; Robert A Wolff; Milind Javle Journal: J Cachexia Sarcopenia Muscle Date: 2014-04-17 Impact factor: 12.910
Authors: An Ngo-Huang; Holly M Holmes; Jude K A des Bordes; Nathan H Parker; David Fogelman; Maria Q B Petzel; Juhee Song; Eduardo Bruera; Matthew H G Katz Journal: Cancer Med Date: 2019-04-29 Impact factor: 4.452
Authors: Nathan H Parker; Jessica Gorzelitz; An Ngo-Huang; Bette J Caan; Laura Prakash; Naveen Garg; Maria Q B Petzel; Keri Schadler; Karen Basen-Engquist; Matthew H G Katz Journal: Integr Cancer Ther Date: 2021 Jan-Dec Impact factor: 3.279
Authors: Elisabeth S Gruber; Gerd Jomrich; Alexandra Kaider; Michael Gnant; Klaus Sahora; Martin Schindl Journal: Ann Surg Oncol Date: 2020-01-03 Impact factor: 5.344
Authors: Patrick Naumann; Jonathan Eberlein; Benjamin Farnia; Jakob Liermann; Thilo Hackert; Jürgen Debus; Stephanie E Combs Journal: Cancers (Basel) Date: 2019-10-26 Impact factor: 6.639